Research output per year
Research output per year
Personal profile
Headline
ASSOCIATE CLINICAL PROFESSOR
Fingerprint
Dive into the research topics where Jesse Cedarbaum is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A qualitative evaluation of the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) by the patient community: a web-based cross-sectional survey
Boyce, D., Robinson, M., Cedarbaum, J. M., Shank, L. M., McDermott, C. J. & van Eijk, R. P. A., 2023, In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24, 3-4, p. 272-280 9 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson's Disease
Mammen, J. R., Speck, R. M., Stebbins, G. M., Müller, M. L. T. M., Yang, P. T., Campbell, M., Cosman, J., Crawford, J. E., Dam, T., Hellsten, J., Jensen-Roberts, S., Kostrzebski, M., Simuni, T., Barowicz, K. W., Cedarbaum, J. M., Dorsey, E. R., Stephenson, D. & Adams, J. L., 2023, In: Journal of Parkinson's Disease. 13, 4, p. 589-607 19 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's Disease
Mammen, J. R., Speck, R. M., Stebbins, G. T., Müller, M. L. T. M., Yang, P. T., Campbell, M., Cosman, J., Crawford, J. E., Dam, T., Hellsten, J., Jensen-Roberts, S., Kostrzebski, M., Simuni, T., Barowicz, K. W., Cedarbaum, J. M., Dorsey, E. R., Stephenson, D. & Adams, J. L., 2023, In: Journal of Parkinson's Disease. 13, 4, p. 619-632 14 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
Parkinson’s Progression Marker Initiative Authors, Steering committee, Study Cores & Industry and Scientific Advisory Board (Acknowledgment), Dec 2022, In: npj Parkinson's Disease. 8, 1, 140.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
Weihofen, A., Liu, Y. T., Arndt, J. W., Huy, C., Quan, C., Smith, B. A., Baeriswyl, J. L., Cavegn, N., Senn, L., Su, L., Marsh, G., Auluck, P. K., Montrasio, F., Nitsch, R. M., Hirst, W. D., Cedarbaum, J. M., Pepinsky, R. B., Grimm, J. & Weinreb, P. H., Apr 2019, In: Neurobiology of Disease. 124, p. 276-288 13 p.Research output: Contribution to journal › Article › peer-review
Open Access114 Scopus citations
Press/Media
-
Australia Patent for 'Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent' Ceases
3/09/21
1 item of Media coverage
Press/Media
-
ImmunoBrain Checkpoint gets $5 million NIA grant to support for phase 1b study of IBC-Ab002 for Alzheimer’s disease treatment
30/08/21
1 item of Media coverage
Press/Media
-
ImmunoBrain Checkpoint gets $5 million NIA grant to support for phase 1b study of IBC-Ab002 for Alzheimer's disease treatment
30/08/21
1 item of Media coverage
Press/Media
-
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002
29/08/21
1 item of Media coverage
Press/Media
-
IMMUNOBRAIN CHECKPOINT AWARDED $5 MILLION US NIA GRANT FOR PHASE 1B ALZHEIMER'S DISEASE PROOF-OF-MECHANISM STUDY OF ANTI-PD-L1 IBC-AB002
27/08/21 → 28/08/21
3 items of Media coverage
Press/Media